{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:41:26Z","timestamp":1762378886952,"version":"build-2065373602"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,5]]},"DOI":"10.7759\/cureus.96162","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:39:46Z","timestamp":1762378786000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Abigail","family":"Rai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh","family":"Kolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav Pratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishu","family":".","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao Yuan","family":"Li Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hariharasudhan","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bendangjungla","family":"Pongen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Joy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid","family":"Sai A.K.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx N","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022, 146:1882-94. 10.1161\/CIRCULATIONAHA.122.059595","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45487","article-title":"Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: a systematic review","volume":"15","author":"Parab P","year":"2023","unstructured":"Parab P, Chaudhary P, Mukhtar S, et al.. Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: a systematic review. Cureus. 2023, 15:e45487. 10.7759\/cureus.45487","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen SL","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019, 7:776-85. 10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0800-2","article-title":"GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","volume":"17","author":"Sposito AC","year":"2018","unstructured":"Sposito AC, Berwanger O, de Carvalho LS, Saraiva JF. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018, 17:157. 10.1186\/s12933-018-0800-2","journal-title":"Cardiovasc Diabetol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-021-00698-5","article-title":"Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?","volume":"13","author":"Melo M","year":"2021","unstructured":"Melo M, Gavina C, Silva-Nunes J, Andrade L, Carvalho D. Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?. Diabetol Metab Syndr. 2021, 13:81. 10.1186\/s13098-021-00698-5","journal-title":"Diabetol Metab Syndr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao H","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024, 384:e076410. 10.1136\/bmj-2023-076410","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50199-y","article-title":"GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease","volume":"15","author":"Pan HC","year":"2024","unstructured":"Pan HC, Chen JY, Chen HY, Yeh FY, Sun CY, Huang TT, Wu VC. GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nat Commun. 2024, 15:5912. 10.1038\/s41467-024-50199-y","journal-title":"Nat Commun"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve SV","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, et al.. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025, 13:15-28. 10.1016\/S2213-8587(24)00271-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00147.2023","article-title":"Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?","volume":"325","author":"Lee B","year":"2023","unstructured":"Lee B, Holstein-Rathlou NH, Sosnovtseva O, S\u00f8rensen CM. Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?. Am J Physiol Cell Physiol. 2023, 325:C243-56. 10.1152\/ajpcell.00147.2023","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/life14111478","article-title":"GLP-1 receptor agonists and diabetic kidney disease: a game changer in the field?","volume":"14","author":"Doumani G","year":"2024","unstructured":"Doumani G, Theofilis P, Tsimihodimos V, Kalaitzidis RG. GLP-1 receptor agonists and diabetic kidney disease: a game changer in the field?. Life (Basel). 2024, 14:10.3390\/life14111478","journal-title":"Life (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar N","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021, 9:653-62. 10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera FB","year":"2024","unstructured":"Rivera FB, Cruz LL, Magalong JV, et al.. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024, 18:100679. 10.1016\/j.ajpc.2024.100679","journal-title":"Am J Prev Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac069","article-title":"GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art","volume":"15","author":"Granata A","year":"2022","unstructured":"Granata A, Maccarrone R, Anzaldi M, et al.. GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. Clin Kidney J. 2022, 15:1657-65. 10.1093\/ckj\/sfac069","journal-title":"Clin Kidney J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13609","article-title":"Glucagon-like peptide-1 receptor agonists and kidney outcomes","volume":"16","author":"MacIsaac RJ","year":"2024","unstructured":"MacIsaac RJ, Trevella P, Ekinci EI. Glucagon-like peptide-1 receptor agonists and kidney outcomes. J Diabetes. 2024, 16:e13609. 10.1111\/1753-0407.13609","journal-title":"J Diabetes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton B","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al.. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015, 162:777-84. 10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta","volume":"10","author":"Owen RK","year":"2019","unstructured":"Owen RK, Bradbury N, Xin Y, Cooper N, Sutton A. MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Synth Methods. 2019, 10:569-81. 10.1002\/jrsm.1373","journal-title":"Res Synth Methods"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01179-1","article-title":"Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis","volume":"19","author":"Dagenais GR","year":"2020","unstructured":"Dagenais GR, Ryd\u00e9n L, Leiter LA, et al.. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol. 2020, 19:199. 10.1186\/s12933-020-01179-1","journal-title":"Cardiovasc Diabetol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12908","article-title":"Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study","volume":"19","author":"Gadde KM","year":"2017","unstructured":"Gadde KM, Vetter ML, Iqbal N, Hardy E, \u00d6hman P. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017, 19:979-88. 10.1111\/dom.12908","journal-title":"Diabetes Obes Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet Lond Engl. 2019, 394:131-8. 10.1016\/S0140-6736(19)31150-X","journal-title":"Lancet Lond Engl"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet Lond Engl. 2019, 394:121-30. 10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet Lond Engl"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein HC","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, et al.. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021, 385:896-907. 10.1056\/NEJMoa2108269","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez AF","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al.. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet Lond Engl. 2018, 392:1519-29. 10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet Lond Engl"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman RR","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al.. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017, 377:1228-39. 10.1056\/NEJMoa1612917","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13927","article-title":"Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial","volume":"22","author":"Hulst AH","year":"2020","unstructured":"Hulst AH, Visscher MJ, Godfried MB, et al.. Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial. Diabetes Obes Metab. 2020, 22:557-65. 10.1111\/dom.13927","journal-title":"Diabetes Obes Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, et al.. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet Lond Engl. 2024, 404:949-61. 10.1016\/S0140-6736(24)01643-X","journal-title":"Lancet Lond Engl"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008323750","article-title":"Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus","volume":"48","author":"Kothare PA","year":"2008","unstructured":"Kothare PA, Linnebjerg H, Isaka Y, et al.. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol. 2008, 48:1389-99. 10.1177\/0091270008323750","journal-title":"J Clin Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057934","article-title":"Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial","volume":"145","author":"Lam CS","year":"2022","unstructured":"Lam CS, Ramasundarahettige C, Branch KR, et al.. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022, 145:565-74. 10.1161\/CIRCULATIONAHA.121.057934","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies KB","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, et al.. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016, 316:500-8. 10.1001\/jama.2016.10260","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer MA","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al.. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015, 373:2247-57. 10.1056\/NEJMoa1509225","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire DK","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, et al.. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025, 392:2001-12. 10.1056\/NEJMoa2501006","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.08.023","article-title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease","volume":"106","author":"Selvarajah V","year":"2024","unstructured":"Selvarajah V, Robertson D, Hansen L, et al.. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 2024, 106:1170-80. 10.1016\/j.kint.2024.08.023","journal-title":"Kidney Int"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45927","article-title":"Safety and efficacy of efpeglenatide in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"15","author":"Escobar J","year":"2023","unstructured":"Escobar J, Monday O, Vemoori Y, et al.. Safety and efficacy of efpeglenatide in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Cureus. 2023, 15:e45927. 10.7759\/cureus.45927","journal-title":"Cureus"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman AM","year":"2022","unstructured":"Shaman AM, Bain SC, Bakris GL, et al.. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022, 145:575-85. 10.1161\/CIRCULATIONAHA.121.055459","journal-title":"Circulation"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen JY","year":"2025","unstructured":"Chen JY, Hsu TW, Liu JH, Pan HC, Lai CF, Yang SY, Wu VC. Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials. Am J Kidney Dis. 2025, 85:555-69.e1. 10.1053\/j.ajkd.2024.11.013","journal-title":"Am J Kidney Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/380124-cardiorenal-safety-markers-with-injectable-glucagon-like-peptide-1-glp-1-agonists-in-type-2-diabetes-a-network-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:39:47Z","timestamp":1762378787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/380124-cardiorenal-safety-markers-with-injectable-glucagon-like-peptide-1-glp-1-agonists-in-type-2-diabetes-a-network-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.96162","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}